What this means
This study is a trial that is still signing up people, so no results exist yet. It will test whether a daily supplement affects aging markers and skin.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 35–55
- Where
- 1 site
The science
- Registered title
- NVTIA® Ergothioneine for Healthy Aging and Skin Health
- Trial ID
- NCT07750002 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Healthy Aging, Skin Aging, Oxidative Stress
- What is tested
- NVTIA® Ergothioneine, Placebo
- Sponsor
- EUROPEAN LIFE SCIENCE RESEARCH ASSOCIATION
- Ages
- 35 Years to 55 Years
- Dates
- First posted Aug 6, 2026 · updated Aug 6, 2026
Registry summary
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of NVTIA® Ergothioneine, a branded ergothioneine ingredient, on healthy aging biomarkers and skin health in healthy adults aged 40 to 65 years. Participants will receive either NVTIA® Ergothioneine or a matching placebo once daily for 12 weeks.
The primary objective of this study is to evaluate the effects of NVTIA® Ergothioneine supplementation on biomarkers associated with oxidative stress and healthy aging. Secondary objectives include assessment of skin elasticity, skin hydration, inflammatory biomarkers, and overall safety. The findings of this study are expected to provide clinical evidence supporting the role of NVTIA® Ergothioneine in promoting healthy aging and maintaining skin health.
Sites (1)
- Dhaka Central International Medical College & Hospital, Dhaka, Bangladesh